Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors

Chiu, Chia-Yu; Ahmed, Sairah; Thomas, Sheeba K.; Wang, Lan Sun; Mustafayev, Khalis; Fayad, Luis; Wierda, William G.; Khawaja, Fareed; Torres, Harrys A.

doi:10.1016/j.clml.2023.04.006

Cited by 10 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bruton tyrosine kinase inhibitors are perceived as moderate risk of HBVr, but current data are insufficient to recommend universal HBVr prophylaxis on these treatments, although close monitoring for HBVr is warranted. 4 , 5 , 12 , 13 Nucleoside inhibitors tenofovir and entecavir are first-line therapy for both HBVr prophylaxis and treatment and have been shown to be superior to lamivudine. 7 …”

Section: Discussionmentioning

confidence: 99%

“… 4 Recently, HBVr was studied in the context of Bruton tyrosine kinase inhibitors, including acalabrutinib, and the HBVr risk was deemed to be moderate-level risk as approximately 10% of patients developed HBVr. 5 , 6 We describe the clinical characteristics, diagnostic challenges, and the clinical course of a single patient who developed HBVr after treatment with acalabrutinib.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Viral Hepatitis B Reactivation With Delayed Cholestatic Effect Secondary to Acalabrutinib

Shaikh,

Abraham,

Wang

et al. 2024

ACG Case Rep J

Self Cite

View full text Add to dashboard Cite

One significant complication of hepatitis B virus includes reactivation (HBVr) in the context of the use of immunosuppressive agents, such as corticosteroids and rituximab, among others. Limited data exist on the topic of HBVr risk in the context of tyrosine kinase inhibitors for which there is no strong guidance recommendation. We describe the clinical characteristics, diagnostic challenges, and the clinical course of a single patient with recurrent mantle cell lymphoma who developed HBVr after treatment with acalabrutinib, a Bruton tyrosine kinase inhibitor.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Viral Hepatitis B Reactivation With Delayed Cholestatic Effect Secondary to Acalabrutinib

Shaikh,

Abraham,

Wang

et al. 2024

ACG Case Rep J

Self Cite

View full text Add to dashboard Cite

show abstract

“…None of these cases experienced HBVr associated hepatitis, and both individuals responded effectively to entecavir treatment. Additionally, Chiu et al [ 4 ] analyzed a series of 29 patients treated with TKIs, reporting 3 cases (10%) of HBVr, with 2 occurring in HBsAg-/anti-HBc+ patients receiving BKT inhibitors. Notably, all 3 experienced HBVr hepatitis, with 2 developing liver failure; all cases recovered with anti-HBV therapy[ 4 ].…”

Section: To the Editormentioning

confidence: 99%

“…Additionally, Chiu et al [ 4 ] analyzed a series of 29 patients treated with TKIs, reporting 3 cases (10%) of HBVr, with 2 occurring in HBsAg-/anti-HBc+ patients receiving BKT inhibitors. Notably, all 3 experienced HBVr hepatitis, with 2 developing liver failure; all cases recovered with anti-HBV therapy[ 4 ]. To note, several cases of HBVr have been reported in patients with solid tumors.…”

Section: To the Editormentioning

confidence: 99%

Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysis

Colapietro,

Pugliese,

Voza

et al. 2024

World J Gastroenterol

View full text Add to dashboard Cite

Hepatitis B virus (HBV) reactivation (HBVr) represents a severe and potentially life-threatening condition, and preventive measures are available through blood test screening or prophylactic therapy administration. The assessment of HBVr traditionally considers factors such as HBV profile, including hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen, along with type of medication (chemotherapy; immunomodulants). Nevertheless, consideration of possible patient’s underlying tumor and the specific malignancy type (solid or hematologic) plays a crucial role and needs to be assessed for decision-making process.

show abstract

“…While BTKi use increases the risk of HBV reactivation, routine prophylaxis lacks sufficient supporting data [ 94 , 213 , 214 ]. Resolved HBV infection requires regular monitoring and pre-emptive antivirals should be initiated upon HBV DNA level rise [ 215 , 216 , 217 , 218 , 219 ]. Patients with positive HBsAg or detectable HBV DNA in resolved infection should receive anti-HBV prophylactic treatment with nucleotide analogs [ 219 ].…”

Section: Infectionsmentioning

confidence: 99%

Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents

Galitzia,

Maccaferri,

Mauro

et al. 2024

Cancers

View full text Add to dashboard Cite

The treatment landscape for CLL has undergone a profound transformation with the advent of targeted agents (TAs) like Bruton’s Tyrosine Kinase inhibitors (BTKis) and BCL-2 inhibitors (BCL-2is). These agents target crucial cellular pathways in CLL, offering superior efficacy over traditional chemo-immunotherapy, which has led to improved progression-free and overall survival rates. This advancement promises enhanced disease control and potentially normal life expectancy for many patients. However, the journey is not without challenges, as these TAs are associated with a range of adverse events (AEs) that can impact treatment efficacy and patient quality of life. This review focuses on detailing the various AEs related to TA management in CLL, evaluating their frequency and clinical impact. The aim is to present a comprehensive guide to the effective management of these AEs, ensuring optimal tolerability and efficacy of TAs. By reviewing the existing literature and consolidating findings, we provide insights into AE management, which is crucial for maximizing patient outcomes in CLL therapy.

show abstract

Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors

Cited by 10 publications

References 12 publications

Viral Hepatitis B Reactivation With Delayed Cholestatic Effect Secondary to Acalabrutinib

Viral Hepatitis B Reactivation With Delayed Cholestatic Effect Secondary to Acalabrutinib

Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysis

Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents

Contact Info

Product

Resources

About